Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.39 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15946008 | 0.85 | AURKA (0.47) | AURKAKDRAURKBBRD4ADRB3 | |
| SCHEMBL3133618 | 0.82 | AURKA (0.45) | AURKAKDRAURKBBRD4ADRB3 | |
| SCHEMBL3135276 | 0.81 | CA1 (0.36) | ADRB3ADRA1AKDM4EALDH1A1 | |
| SCHEMBL2150585 | 0.78 | ADRB3 (0.43) | AURKAKDRAURKBBRD4ADRB3 | |
| SCHEMBL27821304 | 0.78 | CACNA1F (0.45) | AURKAKDRAURKBBRD4ADRB3 | |
| SCHEMBL2151011 | 0.78 | KDM4E (0.40) | ADRB3KDM4E | |
| SCHEMBL2150463 | 0.77 | HTR6 (0.49) | ADRB3HPGDLMNAALDH1A1 | |
| SCHEMBL6301508 | 0.74 | AURKA (0.53) | AURKAKDRAURKBBRD4KDM4E | |
| SCHEMBL13323561 | 0.74 | ADRB3 (0.43) | AURKAKDRAURKBBRD4ADRB3 | |
| SCHEMBL2150835 | 0.73 | CA1 (0.43) | AURKAKDRAURKBBRD4ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-05-26 | — | — | US | disclosed |
| US-9193669-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8674137-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | AURKA 4153/4885KDR 3382/4885AURKB 2597/4885 |
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | AURKA 4153/4885KDR 3382/4885AURKB 2597/4885 |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | AURKA 4153/4885KDR 3382/4885AURKB 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.